Benefits of Apigenin

Evidence-Based Benefits

• GABA-A receptor binding — Avallone et al. (2000) demonstrated apigenin binds the benzodiazepine site on GABA-A receptors with moderate affinity, producing anxiolytic and mild sedative effects without the myorelaxant or amnesic effects of classical benzodiazepines
• Sleep promotion — as the primary active compound in chamomile, apigenin accounts for much of chamomile's clinical sleep and anxiolytic effects documented in the Amsterdam et al. (2009) and Mao et al. (2016) GAD trials
• NAD+ boosting — Escande et al. (2013) showed apigenin inhibits CD38, a major NAD+-consuming enzyme, resulting in increased intracellular NAD+ levels, which supports mitochondrial function and has longevity implications
• Anti-inflammatory effects — apigenin inhibits NF-kB and COX-2 pathways, reducing neuroinflammation that can contribute to anxiety and sleep disturbances
• Neuroprotection — apigenin has demonstrated protective effects against oxidative stress-induced neuronal damage in multiple preclinical models, suggesting long-term brain health benefits alongside acute calming effects

What the Research Says

Apigenin's mechanism is well-characterized at the molecular level. Avallone et al. (2000) demonstrated its GABA-A benzodiazepine site binding, explaining the sedative and anxiolytic effects of chamomile. Escande et al. (2013) revealed the CD38 inhibition / NAD+-boosting mechanism in cell and animal models. However, direct human RCTs with purified apigenin (rather than chamomile extract) are limited. The evidence base largely derives from chamomile trials where apigenin is the presumed primary active compound, and from mechanistic/preclinical studies. The 50mg dose recommendation comes from estimating the apigenin content in clinically effective chamomile extract doses and from Huberman's popularization of this dosage.

Related Conditions